Warning letter
Vilvet Pharmaceutical: warning letter of Feb 25, 2019
FDA warning letter 566336 · Center for Drug Evaluation and Research
Key facts
| Reference number | 566336 |
|---|---|
| Company | Vilvet Pharmaceutical |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Feb 25, 2019 |
| Posted date | Mar 5, 2019 |
| Issuing office | Center for Drug Evaluation and Research |
| Product type | Drugs |
| CFR sections cited | 101.36(e)(1), 101.36(e)(7), 101.4(a)(1), 101.4(g), 101.9(d)(9), 101.13(b)(5), 101.36(b), 101.36(b)(2)(i), 101.36(b)(2)(iii), 101.36(d), 101.36(e)(6), 101.60(b) and 10 more |
| Inspection city | Chester Springs |
| Inspection ZIP | 19425 |
| Inspection start date | Jun 18, 2018 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: